天津医药

天津医药 ›› 2019, Vol. 47 ›› Issue (10): 1050-1053.doi: 10.11958/20191449

• 临床研究 • 上一篇    下一篇

MUC1蛋白在非小细胞肺癌早期诊断中的临床价值

付红艳 1，王义勇 2，张科东 3△，周凤 1   

  1. 1宁夏医科大学临床医学院（邮编750004）；2宁夏医科大学总医院心脏中心，3呼吸与危重症医学科
  • 收稿日期:2019-05-14 修回日期:2019-09-03 出版日期:2019-10-15 发布日期:2019-11-11
  • 通讯作者: 张科东 E-mail:kedong98@163.com
  • 基金资助:
     

Clinical value of MUC1 protein in early diagnosis of non-small cell lung cancer

FU Hong-yan1, WANG Yi-yong2, ZHANG Ke-dong3△, ZHOU Feng1   

  1. 1 Department of Clinical Medical College, Ningxia Medical University, Yinchuan 750004, China; 2 Heart Center, 3 Department of Respiratory and Critical Care Medicine, General Hospital of Ningxia Medical University
  • Received:2019-05-14 Revised:2019-09-03 Published:2019-10-15 Online:2019-11-11
  • Supported by:
     

PDF (PC)

4124

摘要： 摘要：目的 探讨黏蛋白1（MUC1）在不同类型非小细胞肺癌（NSCLC）患者血清和癌组织中的表达情况，并分析 其在NSCLC患者临床早期诊断及治疗中的预测价值。方法 收集2017年12月—2018年12月宁夏医科大学总医院 收治的 34 例肺鳞癌、65 例肺腺癌和 20 例非肺癌患者外周血及肺组织。采用酶联免疫吸附法（ELISA）检测血清 MUC1蛋白表达。所收取肺组织标本均经HE染色证实符合病理要求后，采用免疫组织化学染色法检测MUC1蛋白 表达。采用受试者工作特征（ROC）曲线分析血清中MUC1蛋白预测不同类型NSCLC患者的临床价值。结果 肺鳞 癌和肺腺癌患者血清及癌组织中MUC1蛋白表达水平均高于非肺癌组（P＜0.05）。血清MUC1蛋白诊断肺鳞癌的最 佳临界值为33.23 U/mL，其诊断敏感度为52.94%，特异度为100%；肺鳞癌患者血清及癌组织中的MUC1蛋白阳性表 达率与病理分化程度、TNM分期、年龄、性别均无关（P＞0.05）；血清MUC1蛋白诊断肺腺癌的最佳临界值为31.31 U/ mL，其诊断敏感度为61.54%，特异度为95%；肺腺癌组中-低组织分化、TNM分期Ⅲ~Ⅳ期组患者血清及癌组织MUC1 蛋白阳性表达率分别高于高组织分化、TNM分期Ⅰ~Ⅱ期组（P＜0.05）。结论 NSCLC患者中MUC1蛋白呈高表达， 其对肺腺癌临床早期诊断及治疗可能有预测意义，对肺鳞癌无明显预测意义。

关键词: 黏蛋白-1, 癌, 非小细胞肺, 早期诊断, ROC曲线, 免疫组织化学

Abstract: Abstract：Objective To investigate the expression of MUC1 protein in serum and cancer tissues in patients with different types of non-small cell lung cancer (NSCLC), and to analyze its predictive value in early clinical diagnosis and treatment of NSCLC patients. Methods From December 2017 to December 2018, samples of peripheral blood and lung tissues of 34 cases of lung squamous cell carcinoma, 65 cases of lung adenocarcinoma and 20 cases of non-lung cancer were collected from the General Hospital of Ningxia Medical University. The serum expression of MUC1 protein was detected by enzyme-linked immunosorbent assay (ELISA). After HE staining confirmed that the lung tissue specimens met the pathological requirements, MUC1 protein expression was detected by immunohistochemical staining. The clinical value of serum MUC1 protein for predicting different types of NSCLC patients was performed by ROC curve analysis. Results The expressions of MUC1 protein in serum and cancer tissues were significantly higher in lung squamous cell carcinoma group and lung adenocarcinoma group than those of non-lung cancer group (P＜0.05). The optimum critical value of serum MUC1 protein in the diagnosis of lung squamous cell carcinoma was 33.23 U/mL, with a sensitivity of 52.94% and a specificity of 100%. The positive expression rates of MUC1 proteins in serum and cancer tissues of patients with lung squamous cell carcinoma were not related to the differences of pathological differentiation, TNM stage, age and sex (P＞0.05). The optimal critical value of serum MUC1 protein in the diagnosis of lung adenocarcinoma was 31.31 U/mL, with a sensitivity of 61.54% and a specificity of 95%. The positive expression rates of MUC1 proteins in serum and cancer tissues were significantly higher in lung adenocarcinoma patients with middle-low tissue differentiation and TNM stage Ⅲ-Ⅳ than those of patients with high tissue differentiation and TNM stage Ⅰ-Ⅱ(P＜0.05). Conclusion MUC1 protein is highly expressed in NSCLC patients, which may be of predictive significance for early diagnosis and treatment of lung adenocarcinoma, and has no obvious prognostic significance for lung squamous cell carcinoma.

Key words: mucin-1, carcinoma, non-small-cell lung, early diagnosis, ROC curve, immunohistochemistry

中图分类号: